{"title":"A nuanced review of neoadjuvant therapies in oral cancer.","authors":"Akshat Malik, Kanishk Vishnoi, Vanita Noronha, Kumar Prabhash","doi":"10.1080/14737140.2025.2478891","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Oral squamous cell carcinoma (OSCC) is a significant global health burden. The goals of neoadjuvant chemotherapy (NACT) are to shrink tumors allowing for more conservative surgeries, improve survival and potentially improve quality of life.</p><p><strong>Areas covered: </strong>This review explores the current evidence of utility of NACT in OSCC management. We have covered indications of NACT, types of regimens and their associated toxicities, perioperative challenges with regards to margins and complications. We have also reviewed the upcoming regimens for NACT.</p><p><strong>Expert opinion: </strong>NACT is a potential option for treating borderline resectable and unresectable OSCC. It holds promise for organ preservation (mandibular/tongue). With newer modalities like immunotherapy and targeted therapies, the preferred choice of regimen may evolve. Post NACT, intraoperative margins and choice of adjuvant therapy remain debatable.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2478891","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Oral squamous cell carcinoma (OSCC) is a significant global health burden. The goals of neoadjuvant chemotherapy (NACT) are to shrink tumors allowing for more conservative surgeries, improve survival and potentially improve quality of life.
Areas covered: This review explores the current evidence of utility of NACT in OSCC management. We have covered indications of NACT, types of regimens and their associated toxicities, perioperative challenges with regards to margins and complications. We have also reviewed the upcoming regimens for NACT.
Expert opinion: NACT is a potential option for treating borderline resectable and unresectable OSCC. It holds promise for organ preservation (mandibular/tongue). With newer modalities like immunotherapy and targeted therapies, the preferred choice of regimen may evolve. Post NACT, intraoperative margins and choice of adjuvant therapy remain debatable.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
